VEGF inhibition and cytotoxic effect of aplidin in leukemia cell lines and cells from acute myeloid leukemia

Annals of Oncology

Volumn 16, Issue 10, 2005, Pages 1667-1674

  Biscardi, M ^a   Caporale, R ^a   Balestri, F ^a   Gavazzi, S ^a   Jimeno, J ^b   Grossi, Alberto ^a,c  

^a UNIVERSITY OF FLORENCE   (Italy)

^b PHARMAMAR S A   (Spain)

^c LEONARDO S P A   (Italy)

Author keywords

Aplidine; Marine compounds; Myeloid leukemia; VEGF inhibiton

Indexed keywords

DEHYDRODIDEMNIN B; IDARUBICIN; MESSENGER RNA; VASCULOTROPIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL CYCLE PARAMETERS; CELL GROWTH; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 27144487474     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdi311     Document Type: Article

References (30)

1. Sakai R, Rinehart KL, Kishore V et al. Structure-activity relationships of the didemnins. J Med Chem 1996; 39: 2819-2834.
2. Rinehart KL, Holt TG, Fregeau NL et al. Bioactive compounds from aquatic and terrestrial sources. J Nat Prod 1990; 53: 771-792.
3. Rinehart KL, Gloer JB, Cook JC et al. Structures of the didemnins, antiviral and cytotoxic depsipeptides from a Caribbean tunicate. J Am Chem Soc 1991; 103: 1857-1859.
4. Hendriks HR, Fiebig HH, Giavazzi R et al. Antitumor activity of ET743 against human tumor xenografts from melanoma, non-small-cell lung and ovarian cancer. Ann Oncol 1999; 10: 1233-1240.
5. Jimeno JM, Faircloth GT, Cameron L et al. Progress in the acquisition of new marine-derived anticancer compounds: Development of Ecteinascidin-743 (ET-743). Drugs Future 1996; 21: 1155-1165.
6. Taamma A, Misset JL, Riofrio M et al. Phase I and pharmacokinetics study of ET-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol 2001; 19: 1256-1265.
7. Twelvws C, Hoeckman H, Bowman A et al. Phase I and pharmacokinetic study of Et-743 evaluating a 3-hour intravenous infusion in patients with solid tumors. Clin Cancer Res 1999; 5: 3790s.
8. Faircloth JG, Rinehart K, Nunez de Castro I, Jimeno J. Dehydrodidemnin B, a new marine derived antitumor agent with activity against experimental tumor models. Ann Oncol 1996; 7: 34.
9. Depenbrock H, Peter R, Faircloth GT et al. In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumor cells and haematopoietic precursor cells. Br J Cancer 1998; 78: 739-744.
10. Urdiales JL, Morata P, Nunez de Castro I, Sanchez-Jimenez F. Anti-proliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates. Cancer Lett 1996; 102: 31-37.
11. Lobo C, Garcia-Pozo SG, De Castro IN, Alonso FJ. Effect of dehydrodidemnin B on human colon carcinoma cell lines. Anticancer Res 1997; 17: 333-336.
12. Geldof AA, Mastbergen SC, Hemrar RE, Faircloth GT. Cytotoxicity and neurotoxicity of new marine anticancer agents evaluated using in vitro assay. Cancer Chemother Pharmacol 1999; 44: 312-318.
13. Raymond E, Ady-Vago N, Ribrag V et al. Phase I anti pharmacokinetics study of Aplidine, a marine derived compound, given as 24 h infusion every 2 weeks in patients (PTS) with advanced solid tumors and non-Hodgkin lymphomas (NHL). Ann Oncol 2000; 11: 134.
14. Maroun J, Belanger, Lesleys S et al. Phase I study of Aplidine (APL) in a 1 hour daily infusion ×5 Q 3 weeks in patients (PTS) with advanced solid tumors and low and intermediate grade non Hodgkin lymphomas (NHL): a National Cancer Institute of Canada-Clinical Trials Group (NCIC-CTG) study. Ann Oncol 2000; 11: 134.
15. Raymond E, Paz-Ares L, Izquierdo MA et al. Activity of aplidine, a new marine compound, against medullary thyroid carcinoma (MTC) phase I trials as screening tool for rare tumors. Ann Oncol 2002; 13: 22.
16. Crews CM, Collins JL, Lane WS et al, GTP-dependent binding of the antiproliferative agent didemnin to elongation factor 1-alpha. J Biol Chem 1994; 269: 15411-15414.
17. Erba E, Bassano L, Di Liberti G et al. Cell cycle phase perturbations and apoptosis induced by aplidine. Br J Cancer 2002; 86: 1510-1511.
18. Erba E, Ronzoni S, Bergamaschi D et al. Mechanism of antileukemic activity of Aplidine. Proc Am Assoc Cancer Res 1999; 40: 3.
19. Marchini S, Contegno F, D'Incalci M et al. Gene expression profile in human leukemic MOLT-4 cells treated with the marine compound aplidine. Proc Am Assoc Cancer Res 2000; 41: 833.
20. Broggini M, Marchini SV, Galliera E et al. Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4. Leukemia 2003; 17: 52-59.
21. D'Incalci M, Colombo T, Ubezio P et al. The combination of Yondelis and cisplatin is synergistic against human tumour xenografts. Eur J Cancer 2003; 29: 1920-1926.
22. Bresters D, Broekhuizen A, Faircloth G et al. In vitro cytotoxicity of Aplidine and cross-resistance with other cytotoxic drugs in childhood leukemic and normal bone marrow and blood samples; a rational basis for clinical development. Leukemia 2003; 17: 1338-1343.
23. Scudiero DA, Shoemaker RH, Paull KD et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth anf drug sensitivity in culture using human and other tumor cell lines. Cancer Res 1988; 48: 4827-4833.
24. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptotic flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V, J Immunol Methods 1995; 184: 39-51.
25. Koopman G, Reutelingsperger CP, Kuijten GA et al. Annexin V for flow cytometric detection of phosphatidylserine expression on B cell undergoing apoptosis. Blood 1995; 84: 1415-1420.
26. Möhle R, Green D, Moore M et al. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets., Proc Natl Acad Sci USA 1997; 94: 663-668.
27. Wada H, Saikawa Y, Niida Y et al. Selectively induced high MRP gene expression in multidrug-resistant human HL60 leukemia cells. Exp Hematol 1999; 27: 99-109.
28. Jimeno J, Lopez Martin JA, Ruiz Casado et al. Progress in the clinical development of new marine derived anticancer compounds. Anticancer Drugs 2004; 15: 321-329.
29. Cuadrado A, García-Fernández LF, González L et al. Aplidin induces apoptosis in human cancer cells via glutathioine depletion and sustained activation of epidermal growth factor receptor, Src, Jun N-terminal kinase and p38 kinase. J Biol Chem 2003; 278: 241-250.
30. Cuadrado A, González L, Suárez Y et al. JNK activation is? for Aplidin™-induced apoptosis. Oncogene 2004; 27: 4673-4680.